Thanks. Very conservative by Bell Potter. I feel confident that both valuations have upside. Wait for the H1 A2M results. I think they are about $100m off in sales for FY19.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025